



Viral Epidemiology Snapshot: February 13-19, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	388	14	3.6%
Flu B	388	0	0.0%
RSV	293	3	1.0%
CoV-2 PUI	1105	88	8.0%
CoV-2 Surveillance	412	12	2.9%

Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	291	18	6.2%
Coronavirus 229E	291	6	2.1%
Coronavirus HKU1	291	1	0.3%
Coronavirus NL63	291	2	0.7%
Coronavirus OC43	291	23	7.9%
Metapneumovirus	291	26	8.9%
Rhinovirus/Enterovirus	291	74	25.4%
Parainfluenza 1	291	0	0.0%
Parainfluenza 2	291	0	0.0%
Parainfluenza 3	291	3	1.0%
Parainfluenza 4	291	2	0.7%

Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	5
No Subtype	9
Pending subtype	0

Flu, RSV, & CoV-2 Trends




This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning valley laboratories.

As of 11/14, this report also includes Point-of-Care tests (POCT) for influenza performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

CoV-2 Positivity Rate Trends



Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of 10/31, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

